Kim Monkhorst
Overview
Explore the profile of Kim Monkhorst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
2903
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haberecker M, Ruschoff J, Andriakopoulou C, Gray S, Nackaerts K, de Perrot M, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400675.
PMID: 39938010
Purpose: CD276 (B7-H3) is an immunoregulatory protein that plays an important role in the inhibition of T-cell function. CD276 is overexpressed on a variety of human solid cancer cells with...
2.
Smeenk M, van Diessen J, Boellaard T, Hartemink K, de Vries J, van der Noort V, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39821070
Background: The phase I Induction trial (NCT04287894) assessed the feasibility and safety of induction immunotherapy (IIT) prior to concurrent chemoradiotherapy (cCRT) in patients with locally advanced non-small cell lung cancer...
3.
Marcuse F, Dumoulin D, Hartemink K, Hochstenbag M, Burgers S, Gietema H, et al.
Lung Cancer
. 2024 Dec;
199:108055.
PMID: 39657307
Background: Differentiating benign anterior mediastinal cysts from malignancies is challenging in clinical practice. International guidelines on optimal diagnostics and treatment for anterior mediastinal cystic lesions are lacking. The first part...
4.
Castenmiller S, Kanagasabesan N, Guislain A, Nicolet B, van Loenen M, Monkhorst K, et al.
Oncoimmunology
. 2024 Aug;
13(1):2392898.
PMID: 39188755
Adoptive transfer of tumor infiltrating lymphocytes (TIL therapy) has proven highly effective for treating solid cancers, including non-small cell lung cancer (NSCLC). However, not all patients benefit from this therapy...
5.
van der Wel J, Boelens M, Jebbink M, Smulders S, Maas K, Luitse M, et al.
Neuro Oncol
. 2024 Aug;
26(12):2316-2327.
PMID: 39110039
Background: Diagnosis and treatment of leptomeningeal metastases (LM) in epidermal growth factor receptor mutation-positive (EGFRm +) non-small-cell lung carcinoma (NSCLC) is challenging. We aimed to identify resistance mechanisms (RM) to...
6.
Hummelink K, van der Noort V, Muller M, Schouten R, van den Heuvel M, Thommen D, et al.
PLoS One
. 2024 Jul;
19(7):e0293707.
PMID: 39083541
Background: The efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only in a minority of patients. Multiple biomarkers have been explored to predict treatment benefit,...
7.
Speel E, Dafni U, Thunnissen E, Ruschoff J, OBrien C, Kowalski J, et al.
Lung Cancer
. 2024 Jul;
194:107860.
PMID: 39002492
Background: ROS1 fusion is a relatively low prevalence (0.6-2.0%) but targetable driver in lung adenocarcinoma (LUAD). Robust and low-cost tests, such as immunohistochemistry (IHC), are desirable to screen for patients...
8.
Martin M, Aguilar-Rosas S, Franke K, Pieterse M, van Langelaar J, Schreurs R, et al.
Cancer Immunol Res
. 2024 Apr;
12(6):759-778.
PMID: 38573707
Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate the whole-genome and long-read transcript sequencing of cancers to identify the collection of neo-open reading frame...
9.
Ruiter J, de Langen A, Monkhorst K, Veenhof A, Klomp H, Smit J, et al.
Acta Chir Belg
. 2024 Feb;
124(5):387-395.
PMID: 38404182
Background: Previous studies investigating whether metastatic lymph node count is a relevant prognostic factor in pathological N1 non-small cell lung cancer (NSCLC), showed conflicting results. Hypothesizing that outcome may also...
10.
van de Haar J, Mankor J, Hummelink K, Monkhorst K, Smit E, Wessels L, et al.
Clin Cancer Res
. 2024 Feb;
30(7):1307-1318.
PMID: 38300729
Purpose: The clinical value of STK11, KEAP1, and EGFR alterations for guiding immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) remains controversial, as some patients with these...